Crystal-energy landscapes of active pharmaceutical ingredients using composite approaches

Luc M. LeBlanc,Erin R. Johnson

DOI: https://doi.org/10.1039/c9ce00895k

IF: 3.756

2019-01-01

CrystEngComm

Abstract:Composite methods employing dispersion-corrected DFT consistently identify experimentally isolated polymorphs as the lowest-energy crystal structures of common APIs.

chemistry, multidisciplinary,crystallography

What problem does this paper attempt to address?

Energy partitioning of pharmaceutical cocrystal structures

Birger Dittrich,Lauren Connor,Dominic Werthmueller,Nicole Sykes,Anikó Udvarhelyi

DOI: https://doi.org/10.1039/d2ce00148a

IF: 3.756

2023-01-14

CrystEngComm

Abstract:Active pharmaceutical ingredients (APIs) and selected co-formers were studied in crystalline self-environment, in selected co-crystal structures, and gas phase. To obtain comparable geometries from experimental crystal structures, we rely on fast quantum mechanical GFN2-XTB molecule-in-cluster optimizations. Optimized crystal structures are first analysed in terms of molecule-pair interaction energies, by subdividing a cluster generated from asymmetric unit content through space-group symmetry into pairs of molecules. Accurate energies are then obtained by single-point molecular orbital (MO/MO) two layer "ONIOM" energy partitioning, comparing the same molecules in different crystal environments. Clusters approximate the local environment of a crystal structure for ONIOM. The pre-processor program BAERLAUCH (Acta Cryst A 2012) was used to set up all cluster computations. Solid-state computations using dispersion-corrected density functional theory provide reference results. ONIOM partitioned energies shed light on the driving force of co-crystal formation, with the energy gain from the complementarity of molecule-pair wavefunctions in such structures being the main driving force. It follows that improving prediction of co-crystal structure formation beyond current approaches, e.g. COSMO-RS excess enthalpies, statistics from structural databases or full crystal structure prediction is possible by finding complementary molecule-pairs through conformational sampling, as ultimately exemplified.

chemistry, multidisciplinary,crystallography
Reliable and Practical Computational Prediction of Molecular Crystal Polymorphs

Johannes Hoja,Hsin-Yu Ko,Marcus A. Neumann,Roberto Car,Robert A. DiStasio Jr.,Alexandre Tkatchenko

DOI: https://doi.org/10.1126/sciadv.aau3338

2018-03-21

Abstract:The ability to reliably predict the structures and stabilities of a molecular crystal and its polymorphs without any prior experimental information would be an invaluable tool for a number of fields, with specific and immediate applications in the design and formulation of pharmaceuticals. In this case, detailed knowledge of the polymorphic energy landscape for an active pharmaceutical ingredient yields profound insight regarding the existence and likelihood of late-appearing polymorphs. However, the computational prediction of the structures and stabilities of molecular crystal polymorphs is particularly challenging due to the high dimensionality of conformational and crystallographic space accompanied by the need for relative (free) energies to within $\approx$ 1 kJ/mol per molecule. In this work, we combine the most successful crystal structure sampling strategy with the most accurate energy ranking strategy of the latest blind test of organic crystal structure prediction (CSP), organized by the Cambridge Crystallographic Data Centre (CCDC). Our final energy ranking is based on first-principles density functional theory (DFT) calculations that include three key physical contributions: (i) a sophisticated treatment of Pauli exchange-repulsion and electron correlation effects with hybrid functionals, (ii) inclusion of many-body van der Waals dispersion interactions, and (iii) account of vibrational free energies. In doing so, this combined approach has an optimal success rate in producing the crystal structures corresponding to the five blind-test molecules. With this practical approach, we demonstrate the feasibility of obtaining reliable structures and stabilities for molecular crystals of pharmaceutical importance, paving the way towards an enhanced fundamental understanding of polymorphic energy landscapes and routine industrial application of molecular CSP methods.

Chemical Physics
Polymorph selection of pharmaceutical cocrystals via bench-top and continuous production techniques

Aaron O'Sullivan,Senan Kelly,Shayon Bhattacharya,Kevin M Ryan,Maurice N Collins,Luis Padrela

DOI: https://doi.org/10.1016/j.ijpharm.2024.124596

2024-09-30

Abstract:Polymorphism can be a valuable tool as well as an impediment in the development and approval of pharmaceuticals, providing an opportunity to tune active pharmaceutical ingredient (API) physicochemical properties. The control of polymorphism in cocrystalline systems and other multicomponent forms remains underexplored. The study herein aims to investigate the potential of several techniques, liquid-assisted grinding (LAG), solvent evaporation (SE), supercritical enhanced atomization (SEA) and electrospraying, to control the cocrystal polymorphic outcome of three cocrystals: isonicotinamide-citric acid (IsoCa), ethenzamide-saccharin (EthSac) and ethenzamide-gentisic acid (EthGa). Solvent selection employing LAG and SE showed little effect on polymorphic outcome. Electrospraying and SEA primarily produced the α form of IsoCa, with process parameter variations leading to the β form during SEA, and a mixture of α and γ from electrospraying. Electrospraying led to the stable form I of EthSac, while SEA could produce pure form II, and a mixture. Electrospraying produced the form I of EthGa while SEA could produce form II, with an unknown polymorphic impurity. Density functional theory (DFT) computed electron density (ED) maps of cocrystal polymorph binary systems further rationalised the polymorphic predominance observed through the electrospraying. Ultimately this study provides a general road map for polymorph selection via atomization-based methodologies.
Crystal Polymorph Search in the NPT Ensemble via a Deposition/Sublimation Alchemical Path

Aaron J. Nessler,Okimasa Okada,Yuya Kinoshita,Koki Nishimura,Hiroomi Nagata,Kaori Fukuzawa,Etsuo Yonemochi,Michael J. Schnieders

DOI: https://doi.org/10.1021/acs.cgd.3c01358

IF: 4.01

2024-03-09

Crystal Growth & Design

Abstract:The formulation of active pharmaceutical ingredients involves discovering stable crystal packing arrangements or polymorphs, each of which has distinct pharmaceutically relevant properties. Traditional experimental screening techniques utilizing various conditions are commonly supplemented with in silico crystal structure prediction (CSP) to inform the crystallization process and mitigate risk. Predictions are often based on advanced classical force fields or quantum mechanical calculations that model the crystal potential energy landscape but do not fully incorporate temperature, pressure, or solution conditions during the search procedure. This study proposes an innovative alchemical path that utilizes an advanced polarizable atomic multipole force field to predict crystal structures based on direct sampling of the NPT ensemble. The use of alchemical (i.e., nonphysical) intermediates, a novel Monte Carlo barostat, and an orthogonal space tempering bias combine to enhance the sampling efficiency of the deposition/sublimation phase transition. The proposed algorithm was applied to 2-((4-(2-(3,4-dichlorophenyl)ethyl)phenyl)amino)benzoic acid (Cambridge Crystallography Database Centre ID: XAFPAY) as a case study to showcase the algorithm. Each experimentally determined polymorph with one molecule in the asymmetric unit was successfully reproduced via approximately 1000 short 1 ns simulations per space group where each simulation was initiated from random rigid body coordinates and unit cell parameters. Utilizing two threads of a recent Intel CPU (a Xeon Gold 6330 CPU at 2.00 GHz), 1 ns of sampling using the polarizable AMOEBA force field can be acquired in 4 h (equating to more than 300 ns/day using all 112 threads/56 cores of a dual CPU node) within the Force Field X software (https://ffx.biochem.uiowa.edu). These results demonstrate a step forward in the rigorous use of the NPT ensemble during the CSP search process and open the door to future algorithms that incorporate solution conditions using continuum solvation methods.

chemistry, multidisciplinary,materials science,crystallography
Pharmaceutical Cocrystals: A Novel Systematic Approach for the Administration of Existing Drugs in New Crystalline Form

Aishwarya Savale,Rajendra Mogal,Swati Talele,Sumit Deore,Laxmikant Borse

DOI: https://doi.org/10.13005/bbra/3168

2023-12-31

Biosciences Biotechnology Research Asia

Abstract:ABSTRACT: Poor physicochemical properties like solubility, dissolution profile, stability, etc. of drugs remain as an obstacle to formulation development. In the last two decades, pharmaceutical cocrystal gaining lots of interest from researchers as these physicochemical, mechanical, and pharmacokinetic properties can be altered without compromising the therapeutic effect. The multi-component systems wherein one component is essentially the Active Pharmaceutical Ingredient and another may be either one more drug or coformer are termed as pharmaceutical cocrystal. Cocrystal is a novel, promising, and emerging approach to encountering such problems and improving the performance of pharmaceuticals. The present article describes the types, rationale of design, synthesis methods, and characterization of pharmaceutical cocrystals. In addition to this, challenges before and after synthesizing cocrystal along with currently approved formulations based on the pharmaceutical cocrystal approach and cocrystals under clinical investigation are highlighted.
Crystal Engineering in the design of New Solid Pharmaceutical Forms with enhanced pharmaceutical properties

Javier Ellena

DOI: https://doi.org/10.30609/jeti.v4i03.12950

2021-07-07

Journal of Experimental Techniques and Instrumentation

Abstract:High-efficiency drugs and pharmaceutical formulations, produced in a sustainable way, and that present a favorable performance are widely required in Public Health. Among the pharmacokinetic properties of active pharmaceutical ingredients (APIs), the solubility is main variable since it regulate the availability in the biological target. Numerous formulations on the market and in the National Health System (SUS) present serious drawbacks related to quality, manufacture and performance. In general, APIs are delivered in solid formulations and this characteristic represents a challenge for industry and academia since the therapeutic efficiency of and APIs is related to their crystalline structure, i.d structural multiplicity, polymorphism and composition. APIs may exist in different forms presenting different pharmacokinetic profiles. In addition, the characterization of the diversities of solid forms of an IFA, constitutes an innovative strategy to optimize pharmaceutical properties, providing opportunities for the creation of intellectual property and innovation for the country. In this work we will discuss several strategies related to the problem aiming to show the importance in the pharmaceutical area of solid state techniques like crystal engineering.

English Else
Free Energy Perturbation Approach for Accurate Crystalline Aqueous Solubility Predictions

Richard S Hong,Ana V Rojas,Rajni Miglani Bhardwaj,Lingle Wang,Alessandra Mattei,Nathan S Abraham,Kevin P Cusack,M Olivia Pierce,Sayan Mondal,Nada Mehio,Shailendra Bordawekar,Philip R Kym,Robert Abel,Ahmad Y Sheikh

DOI: https://doi.org/10.1021/acs.jmedchem.3c01339

2023-12-14

Abstract:Early assessment of crystalline thermodynamic solubility continues to be elusive for drug discovery and development despite its critical importance, especially for the ever-increasing fraction of poorly soluble drug candidates. Here we present a detailed evaluation of a physics-based free energy perturbation (FEP+) approach for computing the thermodynamic aqueous solubility. The predictive power of this approach is assessed across diverse chemical spaces, spanning pharmaceutically relevant literature compounds and more complex AbbVie compounds. Our approach achieves predictive (RMSE = 0.86) and differentiating power (R2 = 0.69) and therefore provides notably improved correlations to experimental solubility compared to state-of-the-art machine learning approaches that utilize quantum mechanics-based descriptors. The importance of explicit considerations of crystalline packing in predicting solubility by the FEP+ approach is also highlighted in this study. Finally, we show how computed energetics, including hydration and sublimation free energies, can provide further insights into molecule design to feed the medicinal chemistry DMTA cycle.
Pharmaceutical Digital Design: From Chemical Structure through Crystal Polymorph to Conceptual Crystallization Process

Louise S. Price,Christopher L. Burcham,Michael F. Doherty,Baron G. Peters,Sarah L. Price,Matteo Salvalaglio,Susan M. Reutzel-Edens,Ravi Kumar Reddy Addula,Nicholas Francia,Vikram Khanna

DOI: https://doi.org/10.26434/chemrxiv-2024-lctpz

2024-01-23

Abstract:A workflow for the digital design of crystallization processes starting from the chemical structure of the active pharmaceutical ingredient (API) is a multi-step, multi-disciplinary process. A simple version would be to first predict the API crystal structure and from it the corresponding properties of solubility, morphology, and growth rates, assume that the nucleation would be controlled by seeding, and then use these parameters to design the crystallization process. This is usually an over-simplification as most APIs are polymorphic, and the most stable crystal of the API alone may not have the required properties for development into a drug product. This perspective, from the experience of a Lilly Digital Design project, considers the fundamental theoretical basis of crystal structure prediction (CSP), free energy, solubility, morphology and growth rate prediction, and the current state of nucleation simulation. This is illustrated by applying the modeling techniques to real examples, olanzapine and succinic acid. We demonstrate the promise of using ab initio computer modeling for solid form selection and process design in pharmaceutical development. We also identify open problems in the application of current computational modeling and achieving the accuracy required for immediate implementation that are currently limiting the applicability of the approach.

Chemistry
CRYSTAL STRUCTURE PREDICTION IN THE CONTEXT OF PHARMACEUTICAL POLYMORPH SCREENING AND PUTATIVE POLYMORPHS OF CIPROFLOXACIN

Pawanpreet Singh,Renu Chadha

DOI: https://doi.org/10.22159/ijpps.2017v9i4.14332

2017-02-14

International Journal of Pharmacy and Pharmaceutical Sciences

Abstract:Molecular simulation is increasingly used by medicinal chemists in the process and product development. Reliable computational predictions are of great value not only for the design of an active pharmaceutical ingredient with novel properties but also for the avoidance of an undesirable change of form in the late stages of development of an industrially important molecule. In the pharmaceutical industry, drug polymorphism can be a critical problem and is the subject of various regulatory considerations. This contribution tried to review the fuzzy frontiers between the chemical structure of the molecule and its crystal energy landscape with a particular focus on the crystal structure prediction (csp) methodology to complement polymorph screening. A detailed application of csp in the pharmaceutical industry is illustrated on ciprofloxacin; describing its putative polymorphs. This approach successfully identifies the known crystal form within this class, as well as a large number of other low-energy structures. The performance of the approach is discussed in terms of both the quality of the results and computational aspects. csp methods are now being used as part of the interdisciplinary range of studies to establish the range of solid forms of a molecule. Moreover, further methodological improvements aimed at increasing the accuracy of the predictions and at broadening the range of molecules i.e. cocrystals, salts and solvates.

English Else
A Robust Crystal Structure Prediction Method to Support Small Molecule Drug Development with Large Scale Validation and Prospective Studies

Leif Jacobson,Dong Zhou,Manny Bier,Biswajit Santra,Chuanjie Wu,Peter Skrdla,Paul Devine,Haoyu Yu,Robert Abel,Richard Friesner,Lingle Wang

DOI: https://doi.org/10.26434/chemrxiv-2024-f17zp

2024-01-11

Abstract:Crystal polymorphism is an important and fascinating aspect of solid state chemistry with far reaching implications in the pharmaceuticals, agrisciences, nutraceuticals, battery and aviation industries. Late appearing more stable polymorphs have caused numerous issues in the pharmaceutical industry. Experimental polymorph screening can be very expensive and time consuming, and sometimes may miss important low energy polymorphs due to its inability to exhaust all crystallization conditions. In this paper, we report a crystal structure prediction (CSP) method with unprecedented accuracy and efficiency, validated on a large and diverse dataset including 65 molecules with 135 experimentally found polymorphic forms. The method combines a novel systematic crystal packing search algorithm and the first use of machine learning force fields in a hierarchical crystal energy ranking. Our method not only reproduces all the experimentally known polymorphs, but also suggests new low energy polymorphs yet to be discovered by experiment that might pose potential risks to development of the currently known forms of these compounds. In addition, we also demonstrate, in two prospective drug development projects, how the method was used to accelerate clinical formulation design and derisk downstream processing. The high accuracy, reliability, and efficiency of our method with large scale validations and prospective studies position it for routine molecular crystal structure prediction in drug development.

Chemistry
The computational prediction of pharmaceutical crystal structures and polymorphism

S Price

DOI: https://doi.org/10.1016/j.addr.2003.10.006

IF: 16.1

2004-02-23

Advanced Drug Delivery Reviews

Abstract:A computational method of predicting all the polymorphs of an organic molecule would be a valuable complement to polymorph screening in the developmental phase. Such a computational method is in its early stages of development, and the current methodologies, which are based on searches for the most stable lattice structure, are critically reviewed. This crude thermodynamic approach generally overestimates the propensity for polymorphism, at least for most of the molecules studied so far, showing the need to model kinetic effects as well as to refine the thermodynamic models. Although the ultimate goal of these studies is still far off, computational predictions of crystal structures have proved useful in aiding the characterisation of polymorphs from powder X-ray data, and in providing insights into the range of types of packing that may be adopted by a given molecule. Thus, computational studies already have the potential to be a valuable tool in pharmaceutical solid state science.

pharmacology & pharmacy
Efficient Screening of Coformers for Active Pharmaceutical Ingredient Cocrystallization

Isaac J Sugden,Doris E Braun,David H Bowskill,Claire S Adjiman,Constantinos C Pantelides

DOI: https://doi.org/10.1021/acs.cgd.2c00433

2022-07-06

Abstract:Controlling the physical properties of solid forms for active pharmaceutical ingredients (APIs) through cocrystallization is an important part of drug product development. However, it is difficult to know a priori which coformers will form cocrystals with a given API, and the current state-of-the-art for cocrystal discovery involves an expensive, time-consuming, and, at the early stages of pharmaceutical development, API material-limited experimental screen. We propose a systematic, high-throughput computational approach primarily aimed at identifying API/coformer pairs that are unlikely to lead to experimentally observable cocrystals and can therefore be eliminated with only a brief experimental check, from any experimental investigation. On the basis of a well-established crystal structure prediction (CSP) methodology, the proposed approach derives its efficiency by not requiring any expensive quantum mechanical calculations beyond those already performed for the CSP investigation of the neat API itself. The approach and assumptions are tested through a computational investigation on 30 potential 1:1 multicomponent systems (cocrystals and solvate) involving 3 active pharmaceutical ingredients and 9 coformers and one solvent. This is complemented with a detailed experimental investigation of all 30 pairs, which led to the discovery of five new cocrystals (three API-coformer combinations, a polymorphic cocrystal example, and one with different stoichiometries) and a cis-aconitic acid polymorph. The computational approach indicates that, for some APIs, a significant proportion of all potential API/coformer pairs could be investigated with only a brief experimental check, thereby saving considerable experimental effort.
Free-energy landscape of polymer-crystal polymorphism

Chan Liu,Jan Gerit Brandenburg,Omar Valsson,Kurt Kremer,Tristan Bereau

DOI: https://doi.org/10.48550/arXiv.2007.11867

2020-07-23

Abstract:Polymorphism rationalizes how processing can control the final structure of a material. The rugged free-energy landscape and exceedingly slow kinetics in the solid state have so far hampered computational investigations. We report for the first time the free-energy landscape of a polymorphic crystalline polymer, syndiotactic polystyrene. Coarse-grained metadynamics simulations allow us to efficiently sample the landscape at large. The free-energy difference between the two main polymorphs, $\alpha$ and $\beta$, is further investigated by quantum-chemical calculations. The two methods are in line with experimental observations: they predict $\beta$ as the more stable polymorph at standard conditions. Critically, the free-energy landscape suggests how the $\alpha$ polymorph may lead to experimentally observed kinetic traps. The combination of multiscale modeling, enhanced sampling, and quantum-chemical calculations offers an appealing strategy to uncover complex free-energy landscapes with polymorphic behavior.

Soft Condensed Matter,Chemical Physics
Polymorphism and Crystallization of Active Pharmaceutical Ingredients (APIs)

Jie Lu,Sohrab Rohani

DOI: https://doi.org/10.2174/092986709787549299

IF: 4.74

2009-03-01

Current Medicinal Chemistry

Abstract:Active pharmaceutical ingredients (APIs), frequently delivered to the patient in the solid-state as part of an approved dosage form, can exist in such diverse solid forms as polymorphs, pseudopolymorphs, salts, co-crystals and amorphous solids. Various solid forms often display different mechanical, thermal, physical and chemical properties that can remarkably influence the bioavailability, hygroscopicity, stability and other performance characteristics of the drug. Hence, a thorough understanding of the relationship between the particular solid form of an active pharmaceutical ingredient (API) and its functional properties is important in selecting the most suitable form of the API for development into a drug product. In past decades, there have been significant efforts on the discovery, selection and control of the solid forms of APIs and bulk drugs. This contribution discusses the thermodynamics and kinetics of polymorphic systems, the characterization of polymorphs, and the transformation between polymorphs. The major techniques for polymorph discovery and control developed in the past years are discussed as well.

pharmacology & pharmacy,biochemistry & molecular biology,chemistry, medicinal
Pharmaceutical cocrystals, salts and polymorphs: Advanced characterization techniques

Edyta Pindelska,Agnieszka Sokal,Waclaw Kolodziejski

DOI: https://doi.org/10.1016/j.addr.2017.09.014

IF: 16.1

2017-08-01

Advanced Drug Delivery Reviews

Abstract:The main goal of a novel drug development is to obtain it with optimal physiochemical, pharmaceutical and biological properties. Pharmaceutical companies and scientists modify active pharmaceutical ingredients (APIs), which often are cocrystals, salts or carefully selected polymorphs, to improve the properties of a parent drug. To find the best form of a drug, various advanced characterization methods should be used. In this review, we have described such analytical methods, dedicated to solid drug forms. Thus, diffraction, spectroscopic, thermal and also pharmaceutical characterization methods are discussed. They all are necessary to study a solid API in its intrinsic complexity from bulk down to the molecular level, gain information on its structure, properties, purity and possible transformations, and make the characterization efficient, comprehensive and complete. Furthermore, these methods can be used to monitor and investigate physical processes, involved in the drug development, in situ and in real time. The main aim of this paper is to gather information on the current advancements in the analytical methods and highlight their pharmaceutical relevance.

pharmacology & pharmacy
Surfactant-Polymer Complexation and Competition on Drug Nanocrystal Surfaces Control Crystallinity

Lucas Attia,Dien Nguyen,Devashish Gokhale,Talia Zheng,Patrick S Doyle

DOI: https://doi.org/10.1021/acsami.4c06815

IF: 9.5

2024-06-19

ACS Applied Materials & Interfaces

Abstract:Nanosizing drug crystals has emerged as a successful approach to enabling oral bioavailability, as increasing drug crystal surface area improves dissolution kinetics and effective solubility. Recently, bottom-up methods have been developed to directly assemble nanosized crystals by leveraging polymer and surfactant excipients during crystallization to control crystal size, morphology, and structure. However, while significant research has investigated how polymers and other single additives...

materials science, multidisciplinary,nanoscience & nanotechnology
Discriminating and understanding molecular crystal polymorphism.

Bozhu Chen,Xin Xu

DOI: https://doi.org/10.1002/jcc.27057

2023-01-01

Journal of Computational Chemistry

Abstract:Polymorph discrimination for a molecular crystal has long been a challenging task, which, nonetheless, is a major concern in the pharmaceutical industry. In this work, we have investigated polymorph discrimination on three different molecular crystals, tetrolic acid, oxalic acid, and oxalyl dihydrazide, covering both packing polymorphism and conformational polymorphism. To gain more understanding, we have performed energy decomposition analysis based on many-body expansion, and have compared the results from the XO-PBC method, that is, the eXtended ONIOM method (XO) with the periodic boundary condition (PBC), with those from some commonly used dispersion corrected density functional theory (DFT-D) methods. It is shown here that, with the XYG3 doubly hybrid functional chosen as the target high level to capture the intra- and short-range intermolecular interactions, and the periodic PBE as the basic low level to take long range interactions into account, the XO-PBC(XYG3:PBE) method not only obtains the correct experimental stability orderings, but also predicts reasonable polymorph energy ranges for all three cases. Our results have demonstrated the usefulness of the present theoretical methods, in particular XO-PBC, while highlighted the importance of a better treatment of different kinds of interactions to be beneficial to polymorph control.
Evaluating experimental, knowledge-based and computational cocrystal screening methods to advance drug-drug cocrystal fixed-dose combination development

Alice Parkes,Ahmad Ziaee,Emmet O'Reilly

DOI: https://doi.org/10.1016/j.ejps.2024.106931

2024-12-01

Abstract:Fixed-dose combinations (FDCs) offer significant advantages to patients and the pharmaceutical industry alike through improved dissolution profiles, synergistic effects and extended patent lifetimes. Identifying whether two active pharmaceutical ingredients have the potential to form a drug-drug cocrystal (DDC) or interact is an essential step in determining the most suitable type of FDC to formulate. The lack of coherent strategies to determine if two active pharmaceutical ingredients that can be co-administered can form a cocrystal, has significantly impacted DDC commercialisation. This review aims to accelerate the development of FDCs and DDCs by evaluating existing experimental, knowledge-based and computational cocrystal screening methods; the background of their development, their application in screening for cocrystals and DDCs, and their limitations are discussed. The evaluation provided in this review will act as a guide for selecting suitable screening methods to accelerate FDC development.
Identification and quantification techniques of polymorphic forms - A review

Julian Ticona Chambi,Cinira Fandaruff,Silvia Lucia Cuffini

DOI: https://doi.org/10.1016/j.jpba.2024.116038

IF: 3.571

2024-05-01

Journal of Pharmaceutical and Biomedical Analysis

Abstract:In the pharmaceutical industry, the unexpected appearance of crystalline forms could impact the therapeutic efficacy of an Active Pharmaceutical Ingredient (API). For quality control, a thorough qualitative and quantitative monitoring of pharmaceutical solid forms is essential to ensure the detection and the quantification of crystalline forms, wither different or with the same chemical composition (polymorphs) at a low detection level. The purpose of this paper was to review and highlight the importance of choosing adequate solid-state techniques for detection and quantification APIs that present polymorphism - based on limits of detection (LOD) and quantification (LOQ), pharmacopeias specifications, international guidelines and studies reported in the literature. To this study, the powder X-ray diffraction (PXRD), differential scanning calorimetry (DSC), Infrared and Raman spectroscopies and solid-state nuclear magnetic resonance (NMR) were the solid-state techniques analyzed. Additionally, the Argentine, Brazilian, British, European, International, Japanese, Mexican and the United States of America pharmacopeias were reviewed. Based on the analysis performed, the advantages and disadvantages of these techniques, as well as the LOD and LOQ values of APIs were reported. In comparison to these solid-state techniques, reference material used for identification analyses should be previously identified with the corresponding polymorph. Without this previous procedure, the patterns, the spectra, and DSC curves of the reference material can only be used to confirm the mixture of solid forms, not being able to specify which polymorphs are contained in the sample. A major advantage of PXRD is the use of the calculated diffraction patterns obtained from the Crystallographic Information Frameworks (CIFs) files which could be used as a reference pattern without any other information, assistance technique, or physical standards. Regarding the quantification aspect, different pharmacopeias suggest various methods such as the PXRD combining with Rietveld method, which can be used to obtain lower LOD values for minority phases in the mixture of different substances without the need for a calibration curve. Raman spectroscopy can detect polymorphs in small particles and solid-state NMR spectroscopy is a powerful technique for quantification not only crystalline but also crystalline-amorphous mixtures. Finally, this review intends to be a useful tool to control, with efficiency and accuracy, the polymorphism of APIs in pharmaceutical compounds.

pharmacology & pharmacy,chemistry, analytical

Crystal-energy landscapes of active pharmaceutical ingredients using composite approaches

Energy partitioning of pharmaceutical cocrystal structures

Reliable and Practical Computational Prediction of Molecular Crystal Polymorphs

Polymorph selection of pharmaceutical cocrystals via bench-top and continuous production techniques

Crystal Polymorph Search in the NPT Ensemble via a Deposition/Sublimation Alchemical Path

Pharmaceutical Cocrystals: A Novel Systematic Approach for the Administration of Existing Drugs in New Crystalline Form

Crystal Engineering in the design of New Solid Pharmaceutical Forms with enhanced pharmaceutical properties

Free Energy Perturbation Approach for Accurate Crystalline Aqueous Solubility Predictions

Pharmaceutical Digital Design: From Chemical Structure through Crystal Polymorph to Conceptual Crystallization Process

CRYSTAL STRUCTURE PREDICTION IN THE CONTEXT OF PHARMACEUTICAL POLYMORPH SCREENING AND PUTATIVE POLYMORPHS OF CIPROFLOXACIN

A Robust Crystal Structure Prediction Method to Support Small Molecule Drug Development with Large Scale Validation and Prospective Studies

The computational prediction of pharmaceutical crystal structures and polymorphism

Efficient Screening of Coformers for Active Pharmaceutical Ingredient Cocrystallization

Free-energy landscape of polymer-crystal polymorphism

Polymorphism and Crystallization of Active Pharmaceutical Ingredients (APIs)

Pharmaceutical cocrystals, salts and polymorphs: Advanced characterization techniques

Surfactant-Polymer Complexation and Competition on Drug Nanocrystal Surfaces Control Crystallinity

Discriminating and understanding molecular crystal polymorphism.

Evaluating experimental, knowledge-based and computational cocrystal screening methods to advance drug-drug cocrystal fixed-dose combination development

Identification and quantification techniques of polymorphic forms - A review